Non Small Cell Lung Cancer Clinical Trials in Oklahoma City, Oklahoma

10 studies are recruiting for non small cell lung cancer in Oklahoma City, Oklahoma right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

   Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Clinical Study Site, Oklahoma City, Oklahoma

   Locations

   285 in total

   Run by

   Summit Therapeutics

   See if you can join NCT06767514 on ClinicalTrials.gov

2. A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

   This study will assess if adding sacituzumab tirumotecan with pembrolizumab after surgery is effective in treating NSCLC for participants not achieving pathological complete response. The primary hypothesis of this study is sacituzumab tirumotecan plus pembrolizumab is superior to pembrolizumab mon…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Hightower Clinical, LLC ( Site 0084), Oklahoma City, Oklahoma

   Locations

   269 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06312137 on ClinicalTrials.gov

3. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

   The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

   Stage

   Phase 1

   Ages

   12 and older

   Site

   University of Oklahoma, Oklahoma City, Oklahoma

   Locations

   77 in total

   Run by

   PMV Pharmaceuticals, Inc

   See if you can join NCT04585750 on ClinicalTrials.gov

4. FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

   The purpose of this multicenter, open label trial (NAPISTAR 1-01) is to evaluate the safety/tolerability, pharmacokinetics and preliminary efficacy of TUB-040 and to find the best dose of TUB-040 in participants with ovarian cancer and Non Small Cell Lung Cancer. TUB-040 is an antibody-drug-conjuga…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   OU Health Stephenson Cancer Center, Oklahoma City, Oklahoma

   Locations

   29 in total

   Run by

   Tubulis GmbH

   See if you can join NCT06303505 on ClinicalTrials.gov

5. Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

   This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two substudies (substudy A and substudy B) that will recruit participants according to histological subtypes due to differences in chemotherapy choice…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   INTEGRIS Cancer Institute of Oklahoma, Oklahoma City, Oklahoma

   Locations

   262 in total

   Run by

   BioNTech SE

   See if you can join NCT06712316 on ClinicalTrials.gov

6. Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

   This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Oklahoma - Health Sciences Center, Oklahoma City, Oklahoma

   Locations

   66 in total

   Run by

   Genmab

   See if you can join NCT05579366 on ClinicalTrials.gov

7. Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

   This study is being done to answer the following question: Can the chance of lung cancer growing or spreading be lowered by adding targeted radiotherapy to the usual combination of drugs? This study is being done to find out if this approach is better or worse than the usual approach for lung cance…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma

   Locations

   75 in total

   Run by

   Canadian Cancer Trials Group

   See if you can join NCT06686771 on ClinicalTrials.gov

8. Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

   This is a first-in-human, Phase 1/2, open-label, study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Mavrostobart (PT199) alone and in combination with a PD-1 inhibitor or chemotherapy.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sarah Cannon Research Institute University of Oklahoma, Oklahoma City, Oklahoma

   Locations

   6 in total

   Run by

   Phanes Therapeutics

   See if you can join NCT05431270 on ClinicalTrials.gov

9. GEMINI-NSCLC: NSCLC Biomarker Study

   GEMINI NSCLC Study is a non-interventional study that will be collecting clinical and molecular health information from patients with NSCLC who will receive longitudinal blood collection in addition to their standard of care therapy and disease surveillance with the goals of identifying the molecul…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Hightower Clinical, Oklahoma City, Oklahoma

   Locations

   58 in total

   Run by

   Tempus AI

   See if you can join NCT05236114 on ClinicalTrials.gov

10. A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

    A phase 1a/1b, multicenter, open-label, dose escalation/expansion, multiple-dose study to evaluate the safety and activity of DR-0202 in patients with locally advanced or metastatic, relapsed or refractory carcinomas

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Dren Investigational Site, Oklahoma City, Oklahoma

    Locations

    10 in total

    Run by

    Dren Bio

    See if you can join NCT06999187 on ClinicalTrials.gov